Phaseline

Targets › GPR109A

GPR109A (Hydroxycarboxylic acid receptor 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Apr 2027.

Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. (UniProt, Q8TDS4)

Open in Phaseline: the race on GPR109A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Albert Einstein College of MedicineNicotinic acid
GPR109A receptor agonist; induces vasodilation and affects lipid metabolism
GPR109APhase 2Diabetes MellitusApr 2027

Conditions

Diabetes Mellitus (1)

Modalities

small molecule (1)

Companies

Albert Einstein College of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.